Pharma Tariffs and Drug Pricing: Bernstein Analyst Courtney Breen Discusses Outstanding Questions

Outstanding Questions on Pharma Tariffs

• ❓ Courtney Breen highlights that the recent announcement on pharma tariffs was more of a social media post than a detailed policy, leaving many questions unanswered.
• 🏭 A key uncertainty is the manufacturing in America exclusion, with questions arising about whether a plant used for multiple products or one under construction qualifies for exemption.
• 🌍 The discussion also touches on defining what constitutes sufficient US manufacturing and the extent of tariff exclusion achievable.

Impact of Trade Deals and Import Value

• 🤝 It's confirmed that countries with existing trade deals with the US will have their pharmaceutical companies exempt from tariffs.
• 📈 The US imports approximately $214 billion worth of pharmaceutical products annually, with a significant portion attributed to transfer pricing to accumulate profits in lower-tax regions.
• 🇪🇺 Europe accounts for about 60% of US pharmaceutical imports, and the existing 15% agreement provides a stable framework.
• 🌏 Countries like India and Switzerland, while high-volume contributors, are more associated with lower-cost ingredients and earlier-stage components rather than finished goods.

Drug Pricing as a Primary Investor Concern

• 💰 Drug pricing is identified as the main topic of conversation among investors, overshadowing tariffs which many had already factored in.
• 📉 Investors are concerned about drug pricing as the primary driver of margin multiple compression seen across pharmaceutical companies.
• 🗓️ A critical deadline is approaching on September 29th, after which pricing news is more likely to emerge, as tariffs had served as leverage for the administration.
• ⚠️ The administration has narrower paths to enact changes on drug pricing compared to tariffs, suggesting potential for significant policy shifts.
• 📰 Investors are preparing to digest potential announcements regarding Most Favored Nation policies, direct-to-consumer platforms, and negotiated drug prices under the Inflation Reduction Act.